Shopping Cart 0
Cart Subtotal
USD 0

Asia Pacific Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 2700

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 4300

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 5800

Details

Asia Pacific biosimilars market will grow by 30.7% annually with a total addressable market cap of USD 140.4 billion over 2021-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 33 tables and 56 figures, this 116-page report Asia Pacific Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Recombinant Non-glycosylated Biosimilars

o Insulin

o Recombinant Human Growth Hormone (rHGH)

o Granulocyte Colony Stimulating Factor

o Interferon

Recombinant Glycosylated Biosimilars

o Monoclonal Antibodies (mAb)

o Erythropoietin (EPO)

o Follicle Stimulating Hormone

Recombinant Peptides and Others

o Tumor Necrosis Factor (TNF)-Inhibitor

o Parathyroid Hormone

o Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Cancer

Autoimmune Disease

Blood Disorder

Diabetes

Growth Hormone Deficiency

Infectious Diseases

Other Indications

Based on Manufacturing, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Contract Manufacturing

Inhouse Manufacturing

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Hospitals and Clinics

Research Institutes

Other End Users

Geographically, the following national/local markets are fully investigated:

Japan

China

South Korea

Australia

India

Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

For each key country, detailed analysis and data for annual revenue (USD mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Table Of Content

Scope

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 13

1.2.6 Market Size/Share Estimation 14

1.2.7 Research Limitations 15

1.3 Executive Summary 16

2 Market Overview and Dynamics 19

2.1 Market Size and Forecast 19

2.1.1 Impact of COVID-19 on World Economy 22

2.1.2 Impact of COVID-19 on the Market 25

2.2 Major Growth Drivers 27

2.3 Market Restraints and Challenges 32

2.4 Emerging Opportunities and Market Trends 35

2.5 Porter's Fiver Forces Analysis 39

3 Segmentation of Asia Pacific Market by Product Type 43

3.1 Market Overview by Product Type 43

3.2 Recombinant Non-glycosylated Biosimilars 45

3.2.1 Insulin 47

3.2.2 Recombinant Human Growth Hormone (rHGH) 48

3.2.3 Granulocyte Colony Stimulating Factor 49

3.2.4 Interferon 50

3.3 Recombinant Glycosylated Biosimilars 51

3.3.1 Monoclonal Antibodies (mAb) 52

3.3.2 Erythropoietin (EPO) 53

3.3.3 Follicle Stimulating Hormone 54

3.4 Recombinant Peptides and Others 55

3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 56

3.4.2 Parathyroid Hormone 57

3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 58

4 Segmentation of Asia Pacific Market by Indication 59

4.1 Market Overview by Indication 59

4.2 Cancer 61

4.3 Autoimmune Disease 62

4.4 Blood Disorder 63

4.5 Diabetes 64

4.6 Growth Hormone Deficiency 65

4.7 Infectious Diseases 66

4.8 Other Indications 67

5 Segmentation of Asia Pacific Market by Manufacturing 68

5.1 Market Overview by Manufacturing 68

5.2 Contract Manufacturing 70

5.3 Inhouse Manufacturing 71

6 Segmentation of Asia Pacific Market by End User 72

6.1 Market Overview by End User 72

6.2 Hospitals and Clinics 74

6.3 Research Institutes 75

6.4 Other End Users 76

7 Asia-Pacific Market 2019-2030 by Country 77

7.1 Overview of Asia-Pacific Market 77

7.2 Japan 80

7.3 China 83

7.4 Australia 85

7.5 India 87

7.6 South Korea 89

7.7 Rest of APAC Region 91

8 Competitive Landscape 93

8.1 Overview of Key Vendors 93

8.2 New Product Launch, Partnership, Investment, and M&A 97

8.3 Company Profiles 98

AMEGA Biotech S.A. 98

Apotex Inc. 100

Biocon Ltd 101

Biogen Inc. 102

Boehringer Ingelheim 103

Celltrion, Inc. 104

Dr. Reddy's Laboratories Ltd. 105

Eli Lilly and Company 106

Intas Pharmaceuticals Ltd. 107

LG Chem, Ltd. 108

Merck and Co. Inc. 109

Mylan N.V. 110

Pfizer Inc. 111

Samsung Biologics Co., Ltd. 112

Sandoz International GmbH 113

STADA Arzneimittel AG 114

Teva Pharmaceutical Industries Ltd. 115

RELATED REPORTS 116


List Of Figure

List of Figures:

Figure 1. Research Method Flow Chart 11

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14

Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16

Figure 4. Asia Pacific Biosimilars Market, 2019-2030, USD mn 19

Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 20

Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 20

Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 21

Figure 8. Impact of COVID-19 on Business 25

Figure 9. Primary Drivers and Impact Factors of Asia Pacific Biosimilars Market 27

Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30

Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 30

Figure 12. Primary Restraints and Impact Factors of Asia Pacific Biosimilars Market 32

Figure 13. Investment Opportunity Analysis 36

Figure 14. Porter's Fiver Forces Analysis of Asia Pacific Biosimilars Market 39

Figure 15. Breakdown of Asia Pacific Biosimilars Market by Product Type, 2019-2030, % of Revenue 44

Figure 16. Asia Pacific Addressable Market Cap in 2021-2030 by Product Type, Value (USD mn) and Share (%) 44

Figure 17. Asia Pacific Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, USD mn 45

Figure 18. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, USD mn 47

Figure 19. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, USD mn 48

Figure 20. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, USD mn 49

Figure 21. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, USD mn 50

Figure 22. Asia Pacific Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, USD mn 51

Figure 23. Asia Pacific Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, USD mn 52

Figure 24. Asia Pacific Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, USD mn 53

Figure 25. Asia Pacific Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, USD mn 54

Figure 26. Asia Pacific Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, USD mn 55

Figure 27. Asia Pacific Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, USD mn 56

Figure 28. Asia Pacific Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, USD mn 57

Figure 29. Asia Pacific Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, USD mn 58

Figure 30. Breakdown of Asia Pacific Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 60

Figure 31. Asia Pacific Addressable Market Cap in 2021-2030 by Indication, Value (USD mn) and Share (%) 60

Figure 32. Asia Pacific Biosimilars Market by Indication: Cancer, 2019-2030, USD mn 61

Figure 33. Asia Pacific Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, USD mn 62

Figure 34. Asia Pacific Biosimilars Market by Indication: Blood Disorder, 2019-2030, USD mn 63

Figure 35. Asia Pacific Biosimilars Market by Indication: Diabetes, 2019-2030, USD mn 64

Figure 36. Asia Pacific Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, USD mn 65

Figure 37. Asia Pacific Biosimilars Market by Indication: Infectious Diseases, 2019-2030, USD mn 66

Figure 38. Asia Pacific Biosimilars Market by Indication: Other Indications, 2019-2030, USD mn 67

Figure 39. Breakdown of Asia Pacific Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 69

Figure 40. Asia Pacific Addressable Market Cap in 2021-2030 by Manufacturing, Value (USD mn) and Share (%) 69

Figure 41. Asia Pacific Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, USD mn 70

Figure 42. Asia Pacific Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, USD mn 71

Figure 43. Breakdown of Asia Pacific Biosimilars Market by End User, 2019-2030, % of Revenue 73

Figure 44. Asia Pacific Addressable Market Cap in 2021-2030 by End User, Value (USD mn) and Share (%) 73

Figure 45. Asia Pacific Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, USD mn 74

Figure 46. Asia Pacific Biosimilars Market by End User: Research Institutes, 2019-2030, USD mn 75

Figure 47. Asia Pacific Biosimilars Market by End User: Other End Users, 2019-2030, USD mn 76

Figure 48. Breakdown of APAC Biosimilars Market by Country, 2019 and 2030, % of Revenue 78

Figure 49. Contribution to APAC 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 79

Figure 50. Biosimilars Market in Japan, 2019-2030, USD mn 81

Figure 51. Biosimilars Market in China, 2019-2030, USD mn 83

Figure 52. Biosimilars Market in Australia, 2019-2030, USD mn 85

Figure 53. Biosimilars Market in India, 2019-2030, USD mn 87

Figure 54. Biosimilars Market in South Korea, 2019-2030, USD mn 89

Figure 55. Biosimilars Market in Rest of APAC, 2019-2030, USD mn 91

Figure 56. Growth Stage of Asia Pacific Biosimilars Industry over the Forecast Period 93


List Of Table

List of Tables:

Table 1. Snapshot of Asia Pacific Biosimilars Market in Balanced Perspective, 2019-2030 17

Table 2. Growth Rate of World GDP, 2020-2022 23

Table 3. World Health Spending by Region, USD bn, 2013-2020 31

Table 4. Main Product Trends and Market Opportunities in Asia Pacific Biosimilars Market 35

Table 5. Asia Pacific Biosimilars Market by Product Type, 2019-2030, USD mn 43

Table 6. Asia Pacific Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, USD mn 46

Table 7. Asia Pacific Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, USD mn 51

Table 8. Asia Pacific Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, USD mn 55

Table 9. Asia Pacific Biosimilars Market by Indication, 2019-2030, USD mn 59

Table 10. Asia Pacific Biosimilars Market by Manufacturing, 2019-2030, USD mn 68

Table 11. Asia Pacific Biosimilars Market by End User, 2019-2030, USD mn 72

Table 12. APAC Biosimilars Market by Country, 2019-2030, USD mn 78

Table 13. Japan Biosimilars Market by Product Type, 2019-2030, USD mn 82

Table 14. Japan Biosimilars Market by Indication, 2019-2030, USD mn 82

Table 15. Japan Biosimilars Market by End User, 2019-2030, USD mn 82

Table 16. China Biosimilars Market by Product Type, 2019-2030, USD mn 84

Table 17. China Biosimilars Market by Indication, 2019-2030, USD mn 84

Table 18. China Biosimilars Market by End User, 2019-2030, USD mn 84

Table 19. Australia Biosimilars Market by Product Type, 2019-2030, USD mn 86

Table 20. Australia Biosimilars Market by Indication, 2019-2030, USD mn 86

Table 21. Australia Biosimilars Market by End User, 2019-2030, USD mn 86

Table 22. India Biosimilars Market by Product Type, 2019-2030, USD mn 88

Table 23. India Biosimilars Market by Indication, 2019-2030, USD mn 88

Table 24. India Biosimilars Market by End User, 2019-2030, USD mn 88

Table 25. South Korea Biosimilars Market by Product Type, 2019-2030, USD mn 90

Table 26. South Korea Biosimilars Market by Indication, 2019-2030, USD mn 90

Table 27. South Korea Biosimilars Market by End User, 2019-2030, USD mn 90

Table 28. Biosimilars Market in Rest of APAC by Country/Region, 2019-2030, USD mn 92

Table 29. Breakdown of World Market by Key Vendor, 2020, % 95

Table 30. AMEGA Biotech S.A.: Company Snapshot 98

Table 31. AMEGA Biotech S.A.: Business Segmentation 98

Table 32. AMEGA Biotech S.A.: Product Portfolio 99

Table 33. AMEGA Biotech S.A.: Revenue, 2018-2020, USD mn 99

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Company Profile

Company Profile Title

Asia Pacific biosimilars market will grow by 30.7% annually with a total addressable market cap of USD 140.4 billion over 2021-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 33 tables and 56 figures, this 116-page report Asia Pacific Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Recombinant Non-glycosylated Biosimilars

o Insulin

o Recombinant Human Growth Hormone (rHGH)

o Granulocyte Colony Stimulating Factor

o Interferon

Recombinant Glycosylated Biosimilars

o Monoclonal Antibodies (mAb)

o Erythropoietin (EPO)

o Follicle Stimulating Hormone

Recombinant Peptides and Others

o Tumor Necrosis Factor (TNF)-Inhibitor

o Parathyroid Hormone

o Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Cancer

Autoimmune Disease

Blood Disorder

Diabetes

Growth Hormone Deficiency

Infectious Diseases

Other Indications

Based on Manufacturing, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Contract Manufacturing

Inhouse Manufacturing

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Hospitals and Clinics

Research Institutes

Other End Users

Geographically, the following national/local markets are fully investigated:

Japan

China

South Korea

Australia

India

Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

For each key country, detailed analysis and data for annual revenue (USD mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Scope

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 13

1.2.6 Market Size/Share Estimation 14

1.2.7 Research Limitations 15

1.3 Executive Summary 16

2 Market Overview and Dynamics 19

2.1 Market Size and Forecast 19

2.1.1 Impact of COVID-19 on World Economy 22

2.1.2 Impact of COVID-19 on the Market 25

2.2 Major Growth Drivers 27

2.3 Market Restraints and Challenges 32

2.4 Emerging Opportunities and Market Trends 35

2.5 Porter's Fiver Forces Analysis 39

3 Segmentation of Asia Pacific Market by Product Type 43

3.1 Market Overview by Product Type 43

3.2 Recombinant Non-glycosylated Biosimilars 45

3.2.1 Insulin 47

3.2.2 Recombinant Human Growth Hormone (rHGH) 48

3.2.3 Granulocyte Colony Stimulating Factor 49

3.2.4 Interferon 50

3.3 Recombinant Glycosylated Biosimilars 51

3.3.1 Monoclonal Antibodies (mAb) 52

3.3.2 Erythropoietin (EPO) 53

3.3.3 Follicle Stimulating Hormone 54

3.4 Recombinant Peptides and Others 55

3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 56

3.4.2 Parathyroid Hormone 57

3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 58

4 Segmentation of Asia Pacific Market by Indication 59

4.1 Market Overview by Indication 59

4.2 Cancer 61

4.3 Autoimmune Disease 62

4.4 Blood Disorder 63

4.5 Diabetes 64

4.6 Growth Hormone Deficiency 65

4.7 Infectious Diseases 66

4.8 Other Indications 67

5 Segmentation of Asia Pacific Market by Manufacturing 68

5.1 Market Overview by Manufacturing 68

5.2 Contract Manufacturing 70

5.3 Inhouse Manufacturing 71

6 Segmentation of Asia Pacific Market by End User 72

6.1 Market Overview by End User 72

6.2 Hospitals and Clinics 74

6.3 Research Institutes 75

6.4 Other End Users 76

7 Asia-Pacific Market 2019-2030 by Country 77

7.1 Overview of Asia-Pacific Market 77

7.2 Japan 80

7.3 China 83

7.4 Australia 85

7.5 India 87

7.6 South Korea 89

7.7 Rest of APAC Region 91

8 Competitive Landscape 93

8.1 Overview of Key Vendors 93

8.2 New Product Launch, Partnership, Investment, and M&A 97

8.3 Company Profiles 98

AMEGA Biotech S.A. 98

Apotex Inc. 100

Biocon Ltd 101

Biogen Inc. 102

Boehringer Ingelheim 103

Celltrion, Inc. 104

Dr. Reddy's Laboratories Ltd. 105

Eli Lilly and Company 106

Intas Pharmaceuticals Ltd. 107

LG Chem, Ltd. 108

Merck and Co. Inc. 109

Mylan N.V. 110

Pfizer Inc. 111

Samsung Biologics Co., Ltd. 112

Sandoz International GmbH 113

STADA Arzneimittel AG 114

Teva Pharmaceutical Industries Ltd. 115

RELATED REPORTS 116


List Of Figure

List of Figures:

Figure 1. Research Method Flow Chart 11

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14

Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16

Figure 4. Asia Pacific Biosimilars Market, 2019-2030, USD mn 19

Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 20

Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 20

Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 21

Figure 8. Impact of COVID-19 on Business 25

Figure 9. Primary Drivers and Impact Factors of Asia Pacific Biosimilars Market 27

Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30

Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 30

Figure 12. Primary Restraints and Impact Factors of Asia Pacific Biosimilars Market 32

Figure 13. Investment Opportunity Analysis 36

Figure 14. Porter's Fiver Forces Analysis of Asia Pacific Biosimilars Market 39

Figure 15. Breakdown of Asia Pacific Biosimilars Market by Product Type, 2019-2030, % of Revenue 44

Figure 16. Asia Pacific Addressable Market Cap in 2021-2030 by Product Type, Value (USD mn) and Share (%) 44

Figure 17. Asia Pacific Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, USD mn 45

Figure 18. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, USD mn 47

Figure 19. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, USD mn 48

Figure 20. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, USD mn 49

Figure 21. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, USD mn 50

Figure 22. Asia Pacific Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, USD mn 51

Figure 23. Asia Pacific Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, USD mn 52

Figure 24. Asia Pacific Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, USD mn 53

Figure 25. Asia Pacific Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, USD mn 54

Figure 26. Asia Pacific Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, USD mn 55

Figure 27. Asia Pacific Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, USD mn 56

Figure 28. Asia Pacific Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, USD mn 57

Figure 29. Asia Pacific Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, USD mn 58

Figure 30. Breakdown of Asia Pacific Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 60

Figure 31. Asia Pacific Addressable Market Cap in 2021-2030 by Indication, Value (USD mn) and Share (%) 60

Figure 32. Asia Pacific Biosimilars Market by Indication: Cancer, 2019-2030, USD mn 61

Figure 33. Asia Pacific Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, USD mn 62

Figure 34. Asia Pacific Biosimilars Market by Indication: Blood Disorder, 2019-2030, USD mn 63

Figure 35. Asia Pacific Biosimilars Market by Indication: Diabetes, 2019-2030, USD mn 64

Figure 36. Asia Pacific Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, USD mn 65

Figure 37. Asia Pacific Biosimilars Market by Indication: Infectious Diseases, 2019-2030, USD mn 66

Figure 38. Asia Pacific Biosimilars Market by Indication: Other Indications, 2019-2030, USD mn 67

Figure 39. Breakdown of Asia Pacific Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 69

Figure 40. Asia Pacific Addressable Market Cap in 2021-2030 by Manufacturing, Value (USD mn) and Share (%) 69

Figure 41. Asia Pacific Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, USD mn 70

Figure 42. Asia Pacific Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, USD mn 71

Figure 43. Breakdown of Asia Pacific Biosimilars Market by End User, 2019-2030, % of Revenue 73

Figure 44. Asia Pacific Addressable Market Cap in 2021-2030 by End User, Value (USD mn) and Share (%) 73

Figure 45. Asia Pacific Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, USD mn 74

Figure 46. Asia Pacific Biosimilars Market by End User: Research Institutes, 2019-2030, USD mn 75

Figure 47. Asia Pacific Biosimilars Market by End User: Other End Users, 2019-2030, USD mn 76

Figure 48. Breakdown of APAC Biosimilars Market by Country, 2019 and 2030, % of Revenue 78

Figure 49. Contribution to APAC 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 79

Figure 50. Biosimilars Market in Japan, 2019-2030, USD mn 81

Figure 51. Biosimilars Market in China, 2019-2030, USD mn 83

Figure 52. Biosimilars Market in Australia, 2019-2030, USD mn 85

Figure 53. Biosimilars Market in India, 2019-2030, USD mn 87

Figure 54. Biosimilars Market in South Korea, 2019-2030, USD mn 89

Figure 55. Biosimilars Market in Rest of APAC, 2019-2030, USD mn 91

Figure 56. Growth Stage of Asia Pacific Biosimilars Industry over the Forecast Period 93


List Of Table

List of Tables:

Table 1. Snapshot of Asia Pacific Biosimilars Market in Balanced Perspective, 2019-2030 17

Table 2. Growth Rate of World GDP, 2020-2022 23

Table 3. World Health Spending by Region, USD bn, 2013-2020 31

Table 4. Main Product Trends and Market Opportunities in Asia Pacific Biosimilars Market 35

Table 5. Asia Pacific Biosimilars Market by Product Type, 2019-2030, USD mn 43

Table 6. Asia Pacific Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, USD mn 46

Table 7. Asia Pacific Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, USD mn 51

Table 8. Asia Pacific Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, USD mn 55

Table 9. Asia Pacific Biosimilars Market by Indication, 2019-2030, USD mn 59

Table 10. Asia Pacific Biosimilars Market by Manufacturing, 2019-2030, USD mn 68

Table 11. Asia Pacific Biosimilars Market by End User, 2019-2030, USD mn 72

Table 12. APAC Biosimilars Market by Country, 2019-2030, USD mn 78

Table 13. Japan Biosimilars Market by Product Type, 2019-2030, USD mn 82

Table 14. Japan Biosimilars Market by Indication, 2019-2030, USD mn 82

Table 15. Japan Biosimilars Market by End User, 2019-2030, USD mn 82

Table 16. China Biosimilars Market by Product Type, 2019-2030, USD mn 84

Table 17. China Biosimilars Market by Indication, 2019-2030, USD mn 84

Table 18. China Biosimilars Market by End User, 2019-2030, USD mn 84

Table 19. Australia Biosimilars Market by Product Type, 2019-2030, USD mn 86

Table 20. Australia Biosimilars Market by Indication, 2019-2030, USD mn 86

Table 21. Australia Biosimilars Market by End User, 2019-2030, USD mn 86

Table 22. India Biosimilars Market by Product Type, 2019-2030, USD mn 88

Table 23. India Biosimilars Market by Indication, 2019-2030, USD mn 88

Table 24. India Biosimilars Market by End User, 2019-2030, USD mn 88

Table 25. South Korea Biosimilars Market by Product Type, 2019-2030, USD mn 90

Table 26. South Korea Biosimilars Market by Indication, 2019-2030, USD mn 90

Table 27. South Korea Biosimilars Market by End User, 2019-2030, USD mn 90

Table 28. Biosimilars Market in Rest of APAC by Country/Region, 2019-2030, USD mn 92

Table 29. Breakdown of World Market by Key Vendor, 2020, % 95

Table 30. AMEGA Biotech S.A.: Company Snapshot 98

Table 31. AMEGA Biotech S.A.: Business Segmentation 98

Table 32. AMEGA Biotech S.A.: Product Portfolio 99

Table 33. AMEGA Biotech S.A.: Revenue, 2018-2020, USD mn 99

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)